{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:02:36Z","timestamp":1788458556735,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1097\/jcp.0b013e31825244f6","type":"journal-article","created":{"date-parts":[[2012,4,27]],"date-time":"2012-04-27T09:43:35Z","timestamp":1335519815000},"page":"323-328","source":"Crossref","is-referenced-by-count":45,"title":["Prevalence of Concomitant Oral Antipsychotic Drug Use Among Patients Treated With Long-Acting, Intramuscular, Antipsychotic Medications"],"prefix":"10.1097","volume":"32","author":[{"given":"Neil Krishan","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Sernyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rosenheck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1744-6163.1985.tb00264.x","article-title":"Maintenance medication for chronic schizophrenics: riskbenefit assessment.","volume":"23","author":"Driscoll","year":"1985","journal-title":"Perspect Psychiatr Care"},{"key":"R2-4-20210128","first-page":"6","article-title":"Antipsychotic medication: clinical guidelines for maintenance therapy.","volume":"46","author":"Johnson","year":"1985","journal-title":"J Clin Psychiatry"},{"key":"R3-4-20210128","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003495-199447050-00004","article-title":". Depot antipsychotic drugs. Place in therapy.","volume":"47","author":"Davis","year":"1994","journal-title":"Drugs"},{"key":"R4-4-20210128","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.4088\/JCP.v65n0808","article-title":". Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.","volume":"65","author":"Taylor","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/schbul\/sbm033","article-title":"Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone.","volume":"33","author":"Olfson","year":"2007","journal-title":"Schizophr Bull"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.4088\/JCP.v67n0804","article-title":". A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.","volume":"67","author":"Simpson","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4088\/JCP.v64n1017","article-title":". Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.","volume":"64","author":"Fleischhacker","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11126-009-9111-9","article-title":". Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia.","volume":"80","author":"Mohamed","year":"2009","journal-title":"Psychiatr Q"},{"key":"R9-4-20210128","first-page":"426","article-title":"Depot neuroleptic therapy: an underutilized treatment option.","volume":"53","author":"Glazer","year":"1992","journal-title":"J Clin Psychiatry"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0924-977X(97)00045-X","article-title":". Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy.","volume":"8","author":"Kane","year":"1998","journal-title":"Eur Neuropsychopharmacol"},{"issue":"suppl","key":"R11-4-20210128","first-page":"S9","article-title":"Algorithm for treatment-refractory schizophrenia.","volume":"53","author":"Koshino","year":"1999","journal-title":"Psychiatry Clin Neurosci"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1192\/bjp.195.52.s63","article-title":"Clinical guideline recommendations for antipsychotic long-acting injections.","volume":"52","author":"Kane","year":"2009","journal-title":"Br J Psychiatry Suppl"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2165\/00002512-200320150-00003","article-title":"Long-acting injectable antipsychotics in the elderly: guidelines for effective use.","volume":"20","author":"Masand","year":"2003","journal-title":"Drugs Aging"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00023210-200721060-00001","article-title":"Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics.","volume":"21","author":"Chue","year":"2007","journal-title":"CNS Drugs"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1192\/bjp.179.4.290","article-title":". Systematic meta-review of depot antipsychotic drugs for people with schizophrenia.","volume":"179","author":"Adams","year":"2001","journal-title":"Br J Psychiatry"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1192\/bjp.195.52.s20","article-title":"First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies.","volume":"52","author":"Haddad","year":"2009","journal-title":"Br J Psychiatry Suppl"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":". Oral versus depot antipsychotic drugs for schizophreniaa critical systematic review and meta-analysis of randomised long-term trials.","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophr Res"},{"key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMoa1005987","article-title":". Long-acting risperidone and oral antipsychotics in unstable schizophrenia.","volume":"364","author":"Rosenheck","year":"2011","journal-title":"N Engl J Med"},{"key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1176\/ajp.153.5.682","article-title":"Stability of diagnosis in schizophrenia.","volume":"153","author":"Chen","year":"1996","journal-title":"Am J Psychiatry"},{"key":"R22-4-20210128","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.psychres.2008.11.003","article-title":"Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists.","volume":"175","author":"Jaeger","year":"2010","journal-title":"Psychiatry Res"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/0269881109103133","article-title":". Are depot antipsychotics more coercive than tablets The patients perspective.","volume":"24","author":"Patel","year":"2010","journal-title":"J Psychopharmacol"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4088\/JCP.v69n1004","article-title":". A cross-sectional study of patients perspectives on adherence to antipsychotic medication: depot versus oral.","volume":"69","author":"Patel","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1192\/bjp.195.52.s43","article-title":"Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review.","volume":"52","author":"Waddell","year":"2009","journal-title":"Br J Psychiatry Suppl"},{"key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/0269881108092124","article-title":". Depot and oral antipsychotics: patient preferences and attitudes are not the same thing.","volume":"23","author":"Patel","year":"2009","journal-title":"J Psychopharmacol"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e31825244f6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:59:43Z","timestamp":1620957583000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201206000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31825244f6","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}